vs

Side-by-side financial comparison of EyePoint, Inc. (EYPT) and Waters Corporation (WAT). Click either name above to swap in a different company.

Waters Corporation is the larger business by last-quarter revenue ($932.4M vs $619.0K, roughly 1506.2× EyePoint, Inc.). Waters Corporation runs the higher net margin — 24.2% vs -10922.3%, a 10946.4% gap on every dollar of revenue. On growth, Waters Corporation posted the faster year-over-year revenue change (6.8% vs -94.7%). Over the past eight quarters, Waters Corporation's revenue compounded faster (21.0% CAGR vs -77.0%).

EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.

Waters Corporation is an American company headquartered in Milford, Massachusetts that provides analytical instruments and software used for chromatography, mass spectrometry, laboratory informatics, and rheometry by the life sciences, materials, and food industries.

EYPT vs WAT — Head-to-Head

Bigger by revenue
WAT
WAT
1506.2× larger
WAT
$932.4M
$619.0K
EYPT
Growing faster (revenue YoY)
WAT
WAT
+101.5% gap
WAT
6.8%
-94.7%
EYPT
Higher net margin
WAT
WAT
10946.4% more per $
WAT
24.2%
-10922.3%
EYPT
Faster 2-yr revenue CAGR
WAT
WAT
Annualised
WAT
21.0%
-77.0%
EYPT

Income Statement — Q4 2025 vs Q4 2025

Metric
EYPT
EYPT
WAT
WAT
Revenue
$619.0K
$932.4M
Net Profit
$-67.6M
$225.2M
Gross Margin
61.1%
Operating Margin
-11364.3%
29.0%
Net Margin
-10922.3%
24.2%
Revenue YoY
-94.7%
6.8%
Net Profit YoY
-63.3%
-2.7%
EPS (diluted)
$-0.82
$3.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EYPT
EYPT
WAT
WAT
Q4 25
$619.0K
$932.4M
Q3 25
$966.0K
$799.9M
Q2 25
$5.3M
$771.3M
Q1 25
$24.5M
$661.7M
Q4 24
$11.6M
$872.7M
Q3 24
$10.5M
$740.3M
Q2 24
$9.5M
$708.5M
Q1 24
$11.7M
$636.8M
Net Profit
EYPT
EYPT
WAT
WAT
Q4 25
$-67.6M
$225.2M
Q3 25
$-59.7M
$148.9M
Q2 25
$-59.4M
$147.1M
Q1 25
$-45.2M
$121.4M
Q4 24
$-41.4M
$231.4M
Q3 24
$-29.4M
$161.5M
Q2 24
$-30.8M
$142.7M
Q1 24
$-29.3M
$102.2M
Gross Margin
EYPT
EYPT
WAT
WAT
Q4 25
61.1%
Q3 25
59.0%
Q2 25
58.3%
Q1 25
58.2%
Q4 24
60.1%
Q3 24
93.0%
59.3%
Q2 24
85.2%
59.3%
Q1 24
93.5%
58.9%
Operating Margin
EYPT
EYPT
WAT
WAT
Q4 25
-11364.3%
29.0%
Q3 25
-6420.8%
24.0%
Q2 25
-1166.8%
24.4%
Q1 25
-199.7%
22.9%
Q4 24
-390.4%
33.5%
Q3 24
-311.2%
28.5%
Q2 24
-364.5%
26.7%
Q1 24
-285.2%
21.0%
Net Margin
EYPT
EYPT
WAT
WAT
Q4 25
-10922.3%
24.2%
Q3 25
-6183.4%
18.6%
Q2 25
-1114.3%
19.1%
Q1 25
-184.8%
18.3%
Q4 24
-357.3%
26.5%
Q3 24
-279.0%
21.8%
Q2 24
-325.3%
20.1%
Q1 24
-250.6%
16.0%
EPS (diluted)
EYPT
EYPT
WAT
WAT
Q4 25
$-0.82
$3.76
Q3 25
$-0.85
$2.50
Q2 25
$-0.85
$2.47
Q1 25
$-0.65
$2.03
Q4 24
$-0.65
$3.88
Q3 24
$-0.54
$2.71
Q2 24
$-0.58
$2.40
Q1 24
$-0.55
$1.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EYPT
EYPT
WAT
WAT
Cash + ST InvestmentsLiquidity on hand
$306.1M
$587.8M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$306.1M
$2.6B
Total Assets
$364.0M
$5.1B
Debt / EquityLower = less leverage
0.55×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EYPT
EYPT
WAT
WAT
Q4 25
$306.1M
$587.8M
Q3 25
$204.0M
$459.1M
Q2 25
$255.7M
$367.2M
Q1 25
$318.2M
$382.9M
Q4 24
$370.9M
$325.4M
Q3 24
$253.8M
$331.5M
Q2 24
$280.2M
$327.4M
Q1 24
$299.3M
$338.2M
Total Debt
EYPT
EYPT
WAT
WAT
Q4 25
$1.4B
Q3 25
Q2 25
Q1 25
Q4 24
$1.6B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
EYPT
EYPT
WAT
WAT
Q4 25
$306.1M
$2.6B
Q3 25
$200.2M
$2.3B
Q2 25
$246.0M
$2.2B
Q1 25
$298.4M
$2.0B
Q4 24
$336.5M
$1.8B
Q3 24
$218.7M
$1.6B
Q2 24
$228.3M
$1.4B
Q1 24
$249.9M
$1.3B
Total Assets
EYPT
EYPT
WAT
WAT
Q4 25
$364.0M
$5.1B
Q3 25
$251.7M
$4.9B
Q2 25
$301.1M
$4.7B
Q1 25
$362.6M
$4.6B
Q4 24
$418.5M
$4.6B
Q3 24
$300.9M
$4.5B
Q2 24
$324.2M
$4.4B
Q1 24
$329.2M
$4.5B
Debt / Equity
EYPT
EYPT
WAT
WAT
Q4 25
0.55×
Q3 25
Q2 25
Q1 25
Q4 24
0.89×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EYPT
EYPT
WAT
WAT
Operating Cash FlowLast quarter
$-65.0M
$164.6M
Free Cash FlowOCF − Capex
$-66.0M
FCF MarginFCF / Revenue
-10667.7%
Capex IntensityCapex / Revenue
159.3%
Cash ConversionOCF / Net Profit
0.73×
TTM Free Cash FlowTrailing 4 quarters
$-243.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EYPT
EYPT
WAT
WAT
Q4 25
$-65.0M
$164.6M
Q3 25
$-59.4M
$187.3M
Q2 25
$-62.6M
$41.1M
Q1 25
$-53.1M
$259.6M
Q4 24
$-35.8M
$240.1M
Q3 24
$-39.0M
$204.6M
Q2 24
$-20.2M
$54.5M
Q1 24
$-31.2M
$262.9M
Free Cash Flow
EYPT
EYPT
WAT
WAT
Q4 25
$-66.0M
Q3 25
$-60.2M
Q2 25
$-63.8M
Q1 25
$-53.4M
Q4 24
$-36.2M
Q3 24
$-40.6M
Q2 24
$-21.1M
Q1 24
$-32.4M
FCF Margin
EYPT
EYPT
WAT
WAT
Q4 25
-10667.7%
Q3 25
-6226.9%
Q2 25
-1196.5%
Q1 25
-218.4%
Q4 24
-312.7%
Q3 24
-385.8%
Q2 24
-222.4%
Q1 24
-277.0%
Capex Intensity
EYPT
EYPT
WAT
WAT
Q4 25
159.3%
Q3 25
82.6%
Q2 25
22.9%
Q1 25
1.1%
Q4 24
3.3%
Q3 24
15.0%
Q2 24
9.5%
Q1 24
10.2%
Cash Conversion
EYPT
EYPT
WAT
WAT
Q4 25
0.73×
Q3 25
1.26×
Q2 25
0.28×
Q1 25
2.14×
Q4 24
1.04×
Q3 24
1.27×
Q2 24
0.38×
Q1 24
2.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons